Abstract: An antibacterial imidazolium compound, a photocurable coating composition, and an antibacterial coating film includes a compound represented by Chemical Formula 1 shown below or derivatives thereof. In Chemical Formula 1, description of X?, R1 and, R2 is the same as in the detailed description of the invention. The antibacterial imidazolium compound has excellent antibiosis over various strains, and is included in a photocurable coating composition so as to provide an antibacterial coating film by a simple method. Also, in the antibacterial coating film, the antibacterial imidazolium compound is included as a monomer and chemically bonded to a polymer chain, and thus, antibacterial performance can be maintained for a long period of time.
Type:
Grant
Filed:
February 15, 2013
Date of Patent:
September 15, 2015
Assignee:
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Abstract: Provided are a modified Na-montmorillonite and a preparation method thereof, wherein the content of Na+ in the modified sodium-montmorillonite, calculated as Na2O, is not less than 2.0%. The modified Na-montmorillonite has more reasonable microstructure, higher performance, and better quality. Also provided are a method for preparing a modified nanometered Na-montmorillonite from the modified Na-montmorillonite, and the modified nanometered Na-montmorillonite obtained by the method. Also provided are uses and a pharmaceutical composition of the modified Na-montmorillonite or modified nanometered Na-montmorillonite.
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Abstract: A cosmetic transparent gel preparation that has high levels of transparency and hardness and favorable usability, as well as a gelling agent that is ideal for use in the cosmetic transparent gel preparation. The cosmetic transparent gel preparation contains an esterification reaction product obtained by reacting glycerol with a dibasic acid of 18 to 28 carbon atoms and a fatty acid of 8 to 28 carbon atoms (excluding dibasic acids), 12-hydroxystearic acid, and an oil component. The gelling agent contains an esterification reaction product obtained by reacting glycerol with a dibasic acid of 18 to 28 carbon atoms and a fatty acid of 8 to 28 carbon atoms (excluding dibasic acids), and 12-hydroxystearic acid.
Abstract: The present invention relates to the cosmetic, dermatological or pharmaceutical (therapeutic) use of compounds of formula (I) or a cosmetically acceptable salt of a compound of formula (I) or a mixture containing two or more of these compounds or the salts thereof wherein R1 denotes hydrogen or an organic radical having 1 to 14 carbon atoms, R2 denotes an organic radical having 1 to 14 carbon atoms, and wherein optionally R1 and R2 are covalently bonded to one another, preferably so that a 3 to 8 membered ring is formed, for the lightening of skin and/or hair. The invention further relates to compositions and cosmetic, dermatological or pharmaceutical preparations (compositions) comprising one or more compounds of formula (I) suitable for lightening human skin and/or hair and corresponding methods.
Type:
Grant
Filed:
May 25, 2010
Date of Patent:
June 23, 2015
Assignee:
SYMRISE AG
Inventors:
Gabriele Vielhaber, Heiko Oertling, Karin Schaper, Claudia Gömann, Rahim Brodhage
Abstract: Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them.
Type:
Grant
Filed:
November 8, 2005
Date of Patent:
June 2, 2015
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DU DROIT ET DE LA SANTA-LILLE II
Inventors:
Nicolas Sergeant, Andre Delacourte, Patricia Melnyk, Luc Buee
Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.
Type:
Grant
Filed:
April 10, 2014
Date of Patent:
June 2, 2015
Assignee:
EGALET LTD.
Inventors:
Peter Holm Tygesen, Karsten Lindhardt, Martin Rex Olsen, Gina Engslev Fischer, Jan Martin Overgard, Georg Boye, Nikolaj Skak, Torben Elhauge
Abstract: This invention relates, e.g., to a composition comprising two or more of: (a) N-acetylcysteine and/or (b) simethicone and/or (c) a docusate salt. In one embodiment of the invention, the amounts of (a) and/or (b) and/or (c) are effective, when the composition is administered into a colon of a subject undergoing colonoscopy, to cleanse a region of the colon in the visual field of the colonoscope so that the region contains no adherent stool or intestinal secretions obscuring the visual field. Methods for using this or other compositions of the invention, e.g. to cleanse the colon of a subject in order to enhance visualization of the colon during a colonoscopy, are also described, as are kits for carrying out methods of the invention.
Abstract: Embodiments of topical formulations for administering compound I or a pharmaceutically acceptable salt or solvate thereof are disclosed. Embodiments of methods for using the topical formulations in the treatment of dermatological disorders such as cutaneous collagen vascular diseases, e.g., cutaneous lupus, also are disclosed.
Abstract: The present invention relates to pharmaceutical, nutraceutical, health foods and medical device compositions comprising polysaccharides from Opuntia Ficus Indica cladodes in combination with antioxidant and anti-inflammatory plant extracts as well as those from Olive leaf, Capparis Spinosa buttons, anthocianosides from red oranges, black rice or from other natural sources and their combinations, useful for prevention and therapy of hemorrhoidal disease and related diseases. The invention compositions may, be applied topically or administered by oral route.
Type:
Grant
Filed:
September 1, 2010
Date of Patent:
May 12, 2015
Assignee:
Bionap Srl
Inventors:
Luisa Rizza, Salvatore Munafo, Alberto Serraino
Abstract: The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterized in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble in supercritical CO2 and not being non-crosslinked polyvinylpyrrolidone; b) performing a step of molecular diffusion in the absence of water by contacting, in a static mode without agitation, the mixture obtained in step a) with supercritical CO2 at a pressure of 80 to 170 bars, at a temperature of 31 to 90° C. for 1 to 6 hours; c) recovering the polymer pharmaceutical carrier impregnated with the active substance obtained in step b), the impregnated pharmaceutical carrier being nonporous and being in a solid form and the active substance being in an amorphous form, the method being implemented in the absence of an additional solvent.
Abstract: A compound of formula I: wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, the sum of the carbon atoms in the groups R1 and R2 being at least 10 and preferably 10 to 20, is used to prevent biofilm formation on a surface. The compounds are particularly useful as coatings or treatments for medical devices, including stents, catheters and wire guides.
Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.
Abstract: The present invention relates, e.g., to a system for treating damaged skin, comprising a cosmeceutical formulation comprising about 1-10% of a mixture of perfluorocarbons (PFC's) of at least three different molecular weights, and about 0.001-5% hyaluronic acid (HA) of molecular weight about 100 kDa or less, packaged in an aerosol spray container.
Abstract: The subject invention thus provides a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said at least one phospholipid and uses thereof.
Type:
Grant
Filed:
November 2, 2008
Date of Patent:
March 10, 2015
Assignee:
Enzymotec Ltd.
Inventors:
Fabiana Bar Yosef, Dori Pollod, Ariel Katz